How to build a Biotech company – Strategic deal-making and Equity financing
PennHealthX is excited to host Mr. Steven Holtzman on Thursday 4/4 for our first biotech crash-course series talk this semester. (MS1s: if you recognize the last name, yes it is Bryan’s dad). Mr. Holtzman is currently the President and CEO at Decibel Therapeutics, a clinical-stage biotechnology company that focuses on developing solutions for hearing and balance disorders. www.decibeltx.com.
In the biotech field, he is known as a deal-maker, a reputation he developed at Millennium Pharmaceuticals. Millennium as a “phenomenon” has been well chronicled. They did a Series A venture round at $ 1/share in late-1993. At the height of the “genomics bubble” in 2000, that $1 share was worth $386. For those who are interested, there is a HBS case written about this (attached in this email).
He will be talking to us about how to build a biotech company with strategic deal-making, equity financing and corporate partnering.